Definition and treatment of metabolic dysfunction-associated steatotic liver disease (MASLD)
-
Treatment
There is no effective treatment to date in cases where MASLD has progressed into liver cirrhosis
Definition and treatment of metabolic dysfunction-associated steatohepatitis (MASH)
- Causes liver damage because a lot of fat is accumulated in the liver even when though alcohol has been hardly drunk
- Shows continuous elevation of hepatic enzyme values, and is common to the extent that enough that most cases where there is no history of alcohol intake and hepatitis B and hepatitis C have been serologically excluded correspond to MASH.
- Women account for 75% of the patients, the patients are obese, and 1/3 of the patients are diabetic
- Up to 30% of MASH progresses into hepatocirrhosis within 10 years
The treatment mechanisms of SUNIPla®-M such as antifibrosis, glucose/lipid metabolism control, and antioxidant activity, were confirmed in preclinical animal models of metabolic hepatocirrhosis.
| Project | Indication | Status | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
|
Indication : Metabolic
dysfunction-associated
steatohepatitis
|
Status : preclinical
|
preclinical GLP-Tox P1 |
|||||